| Filed On | Filing |
|---|---|
| 05 Nov 2026 |
8-K: Results of Operations and Financial Condition
-- All ELEVATE-44-201 Cohort 1 participants have completed open-label dosing, with data expected to be received by year-end 2026 -- |
| 14 Oct 2026 |
8-K: Regulation FD Disclosure; Other Events
Entrada Therapeutics Announces Positive Results from the First Cohort of Participants with Duchenne Muscular Dystrophy (DMD) in the Phase 1/2 ELEVATE-45-201 Study of ENTR-601-45 |
| 05 Aug 2026 |
8-K: Results of Operations and Financial Condition
-- Company to report ELEVATE-44-201 data from Cohort 1 open-label period by year-end 2026 -- |
| 10 Jun 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
In accordance with Section 16 of Entrada Therapeutics, Inc. (the “Company”) 2021 Stock Option and Incentive Plan (the “Plan”), the Plan is hereby amended as follows, subject to approval of the Company’s stockholders: |
| 19 May 2026 |
8-K: Regulation FD Disclosure
Meet Andrew and JJ, living with Duchenne muscular dystrophy Corporate Presentation May 2026 |
| 07 May 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
-- Announced positive ELEVATE-44-201 Cohort 1 topline results in Duchenne muscular dystrophy showing favorable safety, tolerability and early functional benefit -- |
| 26 Feb 2026 |
8-K: Results of Operations and Financial Condition
-- Company on track to report ELEVATE-44-201 data from Cohort 1 in Q2 2026 and Cohort 2 by year-end 2026 -- |
| 08 Jan 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure +1 more
Entrada Therapeutics Highlights Progress Across its Portfolio of RNA-based Therapeutics for the Treatment of Neuromuscular and Ocular Diseases |
| 06 Nov 2025 |
8-K: Results of Operations and Financial Condition
-- Company on track to report ELEVATE-44-201 data from first patient cohort in Q2 2026 -- |
| 06 Aug 2025 |
8-K: Results of Operations and Financial Condition
-- First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 -- |
| 11 Jun 2025 |
8-K: Submission of Matters to a Vote of Security Holders
On June 11, 2025, Entrada Therapeutics, Inc. (the “Company”) held its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format via live webcast. Proxies were solicited pursuant to the Company’s definitive proxy... |
| 03 Jun 2025 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
BOSTON, June 3, 2025 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA) today announced the appointment of Maha Radhakrishnan, M.D., to its Board of Directors. |
| 08 May 2025 |
8-K: Results of Operations and Financial Condition
– Receives regulatory authorization in the EU for ELEVATE-44-201, a Phase 1/2 MAD clinical study of ENTR-601-44 in patients living with Duchenne muscular dystrophy who are amenable to exon 44 skipping – |
| 29 Apr 2025 |
8-K: Costs Associated with Exit or Disposal Activities
On April 29, 2025, the board of directors of Entrada Therapeutics, Inc. (the “Company”) approved a strategic plan designed to increase the focus of the Company’s resources on its expanding portfolio of clinical candidates in Duchenne mus... |
| 24 Mar 2025 |
8-K: Regulation FD Disclosure; Other Events
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-45-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-45 in People Living with Duchenne Muscular Dystrophy Amenable to Exon 45 Skipping |
| 27 Feb 2025 |
8-K: Results of Operations and Financial Condition
– Received FDA authorization to initiate ELEVATE-44-102 in the U.S. – |
| 24 Feb 2025 |
8-K: Regulation FD Disclosure; Other Events
– Receives FDA authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 in adults living with Duchenne muscular dystrophy – |
| 03 Feb 2025 |
8-K: Regulation FD Disclosure; Other Events
Entrada Therapeutics Receives Authorization in the United Kingdom to Initiate ELEVATE-44-201, a Phase 1/2 Multiple Ascending Dose Clinical Study of ENTR-601-44 in Patients Living with Duchenne Muscular Dystrophy |
| 15 Jan 2025 |
8-K: Results of Operations and Financial Condition; Other Events
Disclaimer This presentation has been prepared by Entrada Therapeutics, Inc. (the “Company”) and shall not constitute an offer to sell o r a solicitation of an offer to buy securities or an invitation or inducement to engage in investmen... |
| 05 Nov 2024 |
8-K: Results of Operations and Financial Condition
– Presented additional data from the Phase 1 clinical trial ENTR-601-44-101 and new preclinical data supporting ENTR-601-45 for DMD at 2024 World Muscle Society Annual Congress – |
Loading...